EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rebamipide Attenuates Lupus Nephritis by Enhancing Antioxidative Defense in Podocytes: Evidence from a Lupus-Prone Mouse Model

Young-Suk Song, Youngjae Park iD, Da-Som Kim, Se Gwang Jang, Seung-Ki Kwok iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26125809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Young-Suk Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul 06591, R…. Hauptthemen laut MEDLINE: Quinolones, Alanine, Podocytes, Antioxidants. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Education, National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT), Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease that affects various organs, including the kidneys. Despite recent advancements, effective treatment options for renal involvement in SLE remain limited. Rebamipide, originally developed as a gastroprotective agent, has been reported to exert immunomodulatory effects in rheumatic diseases. Here, we aimed to evaluate the therapeutic potential of rebamipide in SLE using an animal model and to elucidate its mechanisms of action. We administered rebamipide or vehicle control to lupus-prone MRL/lpr mice and evaluated its efficacy on lupus-like phenotypes, including renal manifestations and immune cell profiles. Additionally, we investigated potential therapeutic mechanisms through in vitro treatment of murine immune cells and podocytes with rebamipide. Oral administration of rebamipide in lupus-prone mice significantly reduced kidney size, weight, and histopathological inflammation. Among circulating immune cell subsets, only regulatory T cells were significantly increased by rebamipide. In vivo treatment with rebamipide enhanced the expression of podocyte structural proteins, such as Synaptopodin, in kidney tissues, accompanied by the recovery of antioxidative factors, including nuclear factor erythroid 2-related factor 2 (Nrf2). Similarly, in vitro treatment of murine immune cells and podocytes with rebamipide replicated its immunoregulatory and antioxidative effects. Rebamipide is proposed as a potential therapeutic candidate for managing renal involvement in SLE through its antioxidative effects on podocytes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolonesAlaninePodocytesAntioxidantsLupus NephritisAnimalsMiceDisease Models, AnimalFemaleNF-E2-Related Factor 2Mice, Inbred MRL lprOxidative StressKidneyLupus Erythematosus, Systemic

Stichwörter der Autor:innen

animal modelpodocyterebamipidesystemic lupus erythematosus

Substanzen

rebamipideQuinolonesAlanineAntioxidantsNF-E2-Related Factor 2

Autor:innen und Institutionen

  • The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
  • Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

ORCID-Profile: Youngjae Park, Seung-Ki Kwok

Förderung

  • Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Education
  • National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT)
  • Ministry of Education
  • Korea government (MSIT)

Zitieren

APA

Song, Y. S., Park, Y., Kim, D. S., Jang, S. G., & Kwok, S. K. (2025). Rebamipide Attenuates Lupus Nephritis by Enhancing Antioxidative Defense in Podocytes: Evidence from a Lupus-Prone Mouse Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125809

Vancouver

Song YS, Park Y, Kim DS, Jang SG, Kwok SK. Rebamipide Attenuates Lupus Nephritis by Enhancing Antioxidative Defense in Podocytes: Evidence from a Lupus-Prone Mouse Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125809

BibTeX
@article{Song2025,
  author = {Song, Young-Suk and Park, Youngjae and Kim, Da-Som and Jang, Se Gwang and Kwok, Seung-Ki},
  title = {Rebamipide Attenuates Lupus Nephritis by Enhancing Antioxidative Defense in Podocytes: Evidence from a Lupus-Prone Mouse Model},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26125809}
}
Kostenlos starten →